Bixiye
QP30-26 Commercial Pharmacy Benefit Exclusion for Avlayah™ and Qivigy™
Taariikhda uu dhaqangalayo Barnaamijka: May 13, 2026
Natiijooyinka Raadinta
Soo bandhiga 4231 - 4240 ee natiijooyinka 4294
Bixiye
QP38-26 MHCP Pharmacy Benefit Exclusion for Avopef™, Epioxa™ HD/Epioxa, Fesilty™, Midazolam, Photrexa®, and Wainua®
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP37-26 Commercial Pharmacy Benefit Exclusion for Epioxa™ HD/Epioxa, Fensolvi®, Fesilty™, Midazolam, Photrexa®, Wainua®, Zemaira®, and Zoladex®
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP36-26 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP35-26 Intensive Residential Treatment Services (IRTS) Prior Authorization (PA) Requirements
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP34-26 Billing Changes for Opioid Treatment Programs for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
Compounded Medications - Commercial
Formulary Exception, Coverage Exception
Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2026